Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics reported on Thursday a 42 percent increase in its fourth quarter revenues on growing sales and reimbursement of its thyroid tests.

For the three-month period ended Dec. 31, Interpace's revenues climbed to $4.4 million from $3.1 million in the same period the year before. Contributing to the increase was the continued expansion of payor coverage for the company's ThyGenX and ThyraMir tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.